NSI-189 Phosphate Powder

Buy NSI-189 Phosphate Powder Online

NSI-189 Phosphate is a small-molecule neurogenic compound developed to investigate hippocampal neurogenesis and cognitive and mood-related disorders. It progressed through human clinical trials in major depressive disorder.

Product Information

NSI-189 was evaluated in randomized controlled clinical studies using oral doses of 40 and 80 mg/day. Phase 1B research suggested potential effects on depressive and cognitive measures, while the subsequent Phase 2 trial did not significantly improve its primary depression endpoint.

How It Works

NSI-189 was designed to influence neurogenesis, particularly within the hippocampus. Its mechanism differs from traditional antidepressants because it does not primarily depend on monoamine reuptake inhibition.

POTENTIAL BENEFITS

1. Neurogenesis Research

NSI-189 was developed specifically around the concept of stimulating neuronal growth and hippocampal neurogenesis, making it a distinctive compound in neuroscience research.

2. Cognitive Function Research

Human studies included cognitive and physical-functioning assessments, with Phase 1B research reporting exploratory improvements in selected cognitive measures.

3. Mood Research

NSI-189 progressed into clinical trials for major depressive disorder. Although the primary Phase 2 depression endpoint was not statistically significant, several secondary measures showed signals of potential activity.

4. Non-Monoaminergic Approach

NSI-189's proposed neurogenic mechanism differentiates it from conventional antidepressants that primarily target serotonin, norepinephrine, or dopamine reuptake.

Dosage

Human Phase 1B research evaluated 40 mg once daily, 40 mg twice daily, and 40 mg three times daily. A later Phase 2 trial evaluated 40 mg/day and 80 mg/day for 12 weeks. These are clinical-trial doses rather than an established current treatment regimen.

Side Effects

Clinical trials reported generally acceptable short-term tolerability, although adverse events occurred. Because NSI-189 has not become an established mainstream therapy, long-term safety and broader drug-interaction data remain limited.

References

1. Fava M, et al. A Phase 1B, randomized, double blind, placebo-controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016;21(10):1372-1380. PMID: 26643541. PubMed
2. Papakostas GI, et al. A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. Mol Psychiatry. 2020;25(7):1569-1579. PMID: 30626911. PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to access instructions on how to make a payment.

How to Pay